Header Logo

Connection

CLIONA ROONEY to Adult

Back to Details
This is a "connection" page, showing publications CLIONA ROONEY has written about Adult.
CLIONA ROONEY
Connection Strength
0.382
Adult
  1. Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma. J Clin Oncol. 2018 04 10; 36(11):1128-1139.
    View in: PubMed
    Score: 0.036
  2. Vaccination Targeting Native Receptors to Enhance the Function and Proliferation of Chimeric Antigen Receptor (CAR)-Modified T Cells. Clin Cancer Res. 2017 Jul 15; 23(14):3499-3509.
    View in: PubMed
    Score: 0.034
  3. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol. 2014 Mar 10; 32(8):798-808.
    View in: PubMed
    Score: 0.027
  4. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2010 Feb 04; 115(5):925-35.
    View in: PubMed
    Score: 0.020
  5. Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection. Blood. 2002 Dec 01; 100(12):4059-66.
    View in: PubMed
    Score: 0.012
  6. Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs. Blood. 2022 07 07; 140(1):16-24.
    View in: PubMed
    Score: 0.012
  7. Donor-derived multiple leukemia antigen-specific T-cell therapy to prevent relapse after transplant?in patients with ALL. Blood. 2022 04 28; 139(17):2706-2711.
    View in: PubMed
    Score: 0.012
  8. Generation of EBV-specific CD4+ cytotoxic T cells from virus naive individuals. J Immunol. 2002 Jan 15; 168(2):909-18.
    View in: PubMed
    Score: 0.012
  9. Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study. Ann Hematol. 2021 Oct; 100(10):2529-2539.
    View in: PubMed
    Score: 0.011
  10. T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical Effects. J Clin Oncol. 2021 05 01; 39(13):1415-1425.
    View in: PubMed
    Score: 0.011
  11. Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma. J Clin Oncol. 2020 11 10; 38(32):3794-3804.
    View in: PubMed
    Score: 0.011
  12. EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation. Blood. 2018 11 29; 132(22):2351-2361.
    View in: PubMed
    Score: 0.009
  13. HIV-Specific, Ex?Vivo Expanded T Cell Therapy: Feasibility, Safety, and Efficacy in ART-Suppressed HIV-Infected Individuals. Mol Ther. 2018 10 03; 26(10):2496-2506.
    View in: PubMed
    Score: 0.009
  14. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood. 1998 Sep 01; 92(5):1549-55.
    View in: PubMed
    Score: 0.009
  15. Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes. J Clin Invest. 2017 Sep 01; 127(9):3462-3471.
    View in: PubMed
    Score: 0.009
  16. Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation. J Clin Oncol. 2017 Nov 01; 35(31):3547-3557.
    View in: PubMed
    Score: 0.009
  17. HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial. JAMA Oncol. 2017 Aug 01; 3(8):1094-1101.
    View in: PubMed
    Score: 0.009
  18. Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1. Mol Ther. 2017 09 06; 25(9):2202-2213.
    View in: PubMed
    Score: 0.009
  19. Clinical responses with T lymphocytes targeting malignancy-associated ? light chains. J Clin Invest. 2016 07 01; 126(7):2588-96.
    View in: PubMed
    Score: 0.008
  20. Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes. J Allergy Clin Immunol. 2016 05; 137(5):1498-1505.e1.
    View in: PubMed
    Score: 0.008
  21. Production of genetically modified Epstein-Barr virus-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease. J Hematother. 1995 Apr; 4(2):73-9.
    View in: PubMed
    Score: 0.007
  22. Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma. J Clin Oncol. 2015 May 20; 33(15):1688-96.
    View in: PubMed
    Score: 0.007
  23. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood. 2013 Oct 24; 122(17):2965-73.
    View in: PubMed
    Score: 0.007
  24. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood. 2013 Jun 27; 121(26):5113-23.
    View in: PubMed
    Score: 0.006
  25. Generation of polyclonal CMV-specific T cells for the adoptive immunotherapy of glioblastoma. J Immunother. 2012 Feb-Mar; 35(2):159-68.
    View in: PubMed
    Score: 0.006
  26. Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma. Mol Ther. 2011 Dec; 19(12):2258-68.
    View in: PubMed
    Score: 0.006
  27. Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States. Blood. 2011 Jun 02; 117(22):5835-49.
    View in: PubMed
    Score: 0.006
  28. Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma. J Immunother. 2010 Nov-Dec; 33(9):983-90.
    View in: PubMed
    Score: 0.005
  29. Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation. Blood. 2010 Apr 01; 115(13):2695-703.
    View in: PubMed
    Score: 0.005
  30. Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients. Blood. 2009 Mar 12; 113(11):2442-50.
    View in: PubMed
    Score: 0.005
  31. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood. 2007 Oct 15; 110(8):2838-45.
    View in: PubMed
    Score: 0.004
  32. Reconstitution of adenovirus-specific cell-mediated immunity in pediatric patients after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007 Jun; 39(11):677-86.
    View in: PubMed
    Score: 0.004
  33. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med. 2006 Oct; 12(10):1160-6.
    View in: PubMed
    Score: 0.004
  34. Use of cytokine polymorphisms and Epstein-Barr virus viral load to predict development of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients. Clin Transplant. 2006 May-Jun; 20(3):389-93.
    View in: PubMed
    Score: 0.004
  35. Natural killer cell activity following T-cell depleted allogeneic bone marrow transplantation. Br J Haematol. 1986 Mar; 62(3):413-20.
    View in: PubMed
    Score: 0.004
  36. Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease. J Exp Med. 2004 Dec 20; 200(12):1623-33.
    View in: PubMed
    Score: 0.004
  37. Treatment of Epstein-Barr virus lymphoproliferative disease after hematopoietic stem-cell transplantation with hydroxyurea and cytotoxic T-cell lymphocytes. Transplantation. 2004 Sep 15; 78(5):755-7.
    View in: PubMed
    Score: 0.004
  38. Adoptive immunotherapy for posttransplantation viral infections. Biol Blood Marrow Transplant. 2004 Mar; 10(3):143-55.
    View in: PubMed
    Score: 0.003
  39. Induction of antigen-specific regulatory T cells following overexpression of a Notch ligand by human B lymphocytes. J Virol. 2003 Oct; 77(20):10872-80.
    View in: PubMed
    Score: 0.003
  40. The dynamics of herpesvirus and polyomavirus reactivation and shedding in healthy adults: a 14-month longitudinal study. J Infect Dis. 2003 May 15; 187(10):1571-80.
    View in: PubMed
    Score: 0.003
  41. Gamma delta T lymphocyte regeneration after T lymphocyte-depleted bone marrow transplantation from mismatched family members or matched unrelated donors. Bone Marrow Transplant. 1996 Feb; 17(2):243-7.
    View in: PubMed
    Score: 0.002
  42. Administration of neomycin-resistance-gene-marked EBV-specific cytotoxic T lymphocytes to recipients of mismatched-related or phenotypically similar unrelated donor marrow grafts. Hum Gene Ther. 1994 Mar; 5(3):381-97.
    View in: PubMed
    Score: 0.002
  43. Selective lack of antibody to a component of EB nuclear antigen in patients with chronic active Epstein-Barr virus infection. J Infect Dis. 1987 Jul; 156(1):26-35.
    View in: PubMed
    Score: 0.001
  44. Epstein-Barr virus status and tumour cell phenotype in sporadic Burkitt's lymphoma. Int J Cancer. 1986 Mar 15; 37(3):367-73.
    View in: PubMed
    Score: 0.001
  45. Distinctions between endemic and sporadic forms of Epstein-Barr virus-positive Burkitt's lymphoma. Int J Cancer. 1985 Apr 15; 35(4):435-41.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.